Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Bioavailability, and Drug Interaction Study of BIIB091 in Healthy Subjects
NCT04564612Phase 1Completed
- Sponsor
- Biogen
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of biib091 in multiple sclerosis (MS) (4 arms), sponsored by Biogen. Primary endpoints: Time Prior to First Measurable Concentration, Time of Maximum Observed Concentration and 14 more. Started Sep 2020; status: completed.
02
Drugs
biib091
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04564612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564612.